Antioxidant and anti-inflammatory agents mitigate pathology in a mouse model of pseudoachondroplasia

Human Molecular Genetics

Volumn 24, Issue 14, 2015, Pages 3918-3928

  Posey, Karen L ^a   Coustry, Francoise ^a   Veerisetty, Alka C ^a   Hossain, Mohammad ^a   Alcorn, Joseph L ^a   Hecht, Jacqueline T ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Shriners Hospital for Children   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CARTILAGE OLIGOMERIC MATRIX PROTEIN; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA; ACETYLSALICYLIC ACID; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; ENDOPLASMIC RETICULUM STRESS; FEMUR; GROWTH PLATE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FOLDING; PSEUDOACHONDROPLASIA; QUALITY CONTROL; SHORT LIMBED DWARFISM; ACHONDROPLASIA; ANIMAL; CHONDROCYTE; DISEASE MODEL; DRUG EFFECTS; EPIPHYSIS PLATE; GENETICS; INFLAMMATION; METABOLISM; MUTATION; PATHOLOGY;

MUS;

ACHONDROPLASIA; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ASPIRIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CELL PROLIFERATION; CHONDROCYTES; DISEASE MODELS, ANIMAL; GROWTH PLATE; INFLAMMATION; MICE; MUTATION; STILBENES;

EID: 84936773256     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv122     Document Type: Article

References (72)

1. Hecht, J.T., Deere, M., Putnam, E., Cole, W., Vertel, B., Chen, H. and Lawler, J. (1998) Characterization of cartilage oligomeric matrix protein (COMP) in human normal and pseudoachondroplasia musculoskeletal tissues. Matrix Biol., 17, 269-278.
2. Hedbom, E., Antonsson, P., Hjerpe, A., Aeschlimann, D., Paulsson, M., Rosa-Pimentel, E., Sommarin, Y., Wendel, M., Oldberg, A. and Heinegard, D. (1992) Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J. Biol. Chem., 267, 6132-6136.
3. Fang, C., Carlson, C.S., Leslie, M.P., Tulli, H., Stolerman, E., Perris, R., Ni, L. and Di Cesare, P.E. (2000) Molecular cloning, sequencing, and tissue and developmental expression of mouse cartilage oligomeric matrix protein (COMP). J. Orthop. Res., 18, 593-603.
4. Merritt, T.M., Bick, R., Poindexter, B.J., Alcorn, J.L. and Hecht, J.T. (2007) Unique matrix structure in the rough endoplasmic reticulum cisternae of pseudoachondroplasia chondrocytes. Am. J. Pathol., 170, 293-300.
5. Thur, J., Rosenberg, K., Nitsche, D.P., Pihlajamaa, T., Ala-Kokko, L., Heinegard, D., Paulsson, M. and Maurer, P. (2001) Mutations in cartilage oligomeric matrix protein causing pseudoachondroplasia and multiple epiphyseal dysplasia affect binding of calcium and collagen I, II, and IX. J. Biol. Chem., 276, 6083-6092.
6. Bleasel, J.F., Poole, A.R., Heinegard, D., Saxne, T., Holderbaum, D., Ionescu, M., Jones, P. and Moskowitz, R.W. (1999) Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. Arthritis Rheum., 42, 39-45.
7. Lohmander, L.S., Saxne, T. and Heinegard, D.K. (1994) Release of cartilage oligomericmatrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann. Rheum. Dis., 53, 8-13.
8. Mann, H.H., Ozbek, S., Engel, J., Paulsson, M. andWagener, R. (2004) Interactions between the cartilage oligomeric matrix protein and matrilins. Implications for matrix assembly and the pathogenesis of chondrodysplasias. J. Biol. Chem., 279, 25294-25298.
9. Xu, K., Zhang, Y., Ilalov, K., Carlson, C.S., Feng, J.Q., Di Cesare, P.E. and Liu, C.J. (2007) Cartilage oligomeric matrix protein associates with granulin-epithelin precursor (GEP) and potentiates GEP-stimulated chondrocyte proliferation. J. Biol. Chem., 282, 11347-11355.
10. Chen, F.H., Thomas, A.O., Hecht, J.T., Goldring, M.B. and Lawler, J. (2005) Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins. J. Biol. Chem., 280, 32655-32661.
11. Unger, S. and Hecht, J.T. (2001) Pseudoachondroplasia and multiple epiphyseal dysplasia: new etiologic developments. Am. J. Med. Genet., 106, 244-250.
12. McKeand, J., Rotta, J. and Hecht, J.T. (1996) Natural history study of pseudoachondroplasia. Am. J. Med. Genet., 63, 406-410.
13. Hecht, J.T., Makitie, O., Hayes, E., Haynes, R., Susic, M., Montufar-Solis, D., Duke, P.J. and Cole, W.G. (2004) Chondrocyte cell death and intracellular distribution of COMP and type IX collagen in the pseudoachondroplasia growth plate. J. Orthop. Res., 22, 759-767.
14. Hecht, J.T., Montufar-Solis, D., Decker, G., Lawler, J., Daniels, K. and Duke, P.J. (1998) Retention of cartilage oligomeric matrix protein (COMP) and cell death in redifferentiated pseudoachondroplasia chondrocytes. Matrix Biol., 17, 625-633.
15. Merritt, T.M., Alcorn, J.L., Haynes, R. and Hecht, J.T. (2006) Expression of mutant cartilage oligomeric matrix protein in human chondrocytes induces the pseudoachondroplasia phenotype. J. Orthop. Res., 24, 700-707.
16. Posey, K.L. and Hecht, J.T. (2008) The role of cartilage oligomeric matrix protein (COMP) in skeletal disease. Curr. Drug Targets, 9, 869-877.
17. Deere, M., Sanford, T., Ferguson, H.L., Daniels, K. and Hecht, J.T. (1998) Identification of twelve mutations in cartilage oligomeric matrix protein (COMP) in patients with pseudoachondroplasia. Am. J. Med. Genet., 80, 510-513.
18. Deere, M., Sanford, T., Francomano, C.A., Daniels, K. and Hecht, J.T. (1999) Identification of nine novel mutations in cartilage oligomeric matrix protein in patients with pseudoachondroplasia and multiple epiphyseal dysplasia. Am. J. Med. Genet., 85, 486-490.
19. Posey, K.L., Veerisetty, A.C., Liu, P., Wang, H.R., Poindexter, B.J., Bick, R., Alcorn, J.L. and Hecht, J.T. (2009) An inducible cartilage oligomeric matrix protein mouse model recapitulates human pseudoachondroplasia phenotype. Am. J. Pathol., 175, 1555-1563.
20. Posey, K.L., Coustry, F., Veerisetty, A.C., Liu, P., Alcorn, J.L. and Hecht, J.T. (2012) Chop (Ddit3) is essential for D469del-COMP retention and cell death in chondrocytes in an inducible transgenic mouse model of pseudoachondroplasia. Am. J. Pathol., 180, 727-737.
21. Posey, K.L., Coustry, F., Veerisetty, A.C., Liu, P., Alcorn, J.L. and Hecht, J.T. (2014) Chondrocyte-specific pathology during skeletal growth and therapeutics in a murine model of pseudoachondroplasia. J. Bone Miner. Res., 29, 1258-1268.
22. Malhotra, J.D. and Kaufman, R.J. (2007) Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a doubleedged sword? Antioxid. Redox. Signal, 9, 2277-2293.
23. Gotoh, T., Endo, M. and Oike, Y. (2011) Endoplasmic reticulum stress-related inflammation and cardiovascular diseases. Int. J. Inflam., 2011, 259462.
24. Salminen, A., Kauppinen, A., Suuronen, T., Kaarniranta, K. and Ojala, J. (2009) ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology. J. Neuroinflammation, 6, 41.
25. Cullinan, S.B. and Diehl, J.A. (2006) Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int. J. Biochem. Cell. Biol., 38, 317-332.
26. Hotamisligil, G.S. (2010) Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell, 140, 900-917.
27. Malhotra, J.D., Miao, H., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S.W. and Kaufman, R.J. (2008) Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc. Natl. Acad. Sci. U. S. A., 105, 18525-18530.
28. Yamazaki, T., Muramoto, M., Oe, T., Morikawa, N., Okitsu, O., Nagashima, T., Nishimura, S., Katayama, Y. and Kita, Y. (2006) Diclofenac, a non-steroidal anti-inflammatory drug, suppresses apoptosis induced by endoplasmic reticulum stresses by inhibiting caspase signaling. Neuropharmacology, 50, 558-567.
29. Hosoi, T., Yamaguchi, R., Noji, K., Matsuo, S., Baba, S., Toyoda, K., Suezawa, T., Kayano, T., Tanaka, S. and Ozawa, K. (2014) Flurbiprofen ameliorated obesity by attenuating leptin resistance induced by endoplasmic reticulum stress. EMBO Mol. Med., 6, 335-346.
30. Hosoi, T., Sasaki, M., Baba, S. and Ozawa, K. (2009) Effect of pranoprofen on endoplasmic reticulum stress in the primary cultured glial cells. Neurochem. Int., 54, 1-6.
31. Cong, X.D., Ding, M.J., Dai, D.Z., Wu, Y., Zhang, Y. and Dai, Y. (2012) ER stress, p66shc, and p-Akt/Akt mediate adjuvant-induced inflammation, which is blunted by argirein, a supermolecule and rhein in rats. Inflammation, 35, 1031-1040.
32. Coustry, F., Posey, K.L., Liu, P., Alcorn, J.L. and Hecht, J.T. (2012) D469del-COMP retention in chondrocytes stimulates caspase-independent necroptosis. Am. J. Pathol., 180, 738-748.
33. Cooper, R.R., Ponseti, I.V. and Maynard, J.A. (1973) Pseudoachondroplastic dwarfism. A rough-surfaced endoplasmic reticulum storage disorder. J. Bone Joint Surg., 55, 475-484.
34. Warman, M.L., Cormier-Daire, V., Hall, C., Krakow, D., Lachman, R., LeMerrer, M., Mortier, G., Mundlos, S., Nishimura, G., Rimoin, D.L. et al. (2011) Nosology and classification of genetic skeletal disorders: 2010 revision. Am. J. Med. Genet. A, 155A, 943-968.
35. Hecht, J.T., Nelson, L.D., Crowder, E., Wang, Y., Elder, F.F., Harrison, W.R., Francomano, C.A., Prange, C.K., Lennon, G.G., Deere, M. et al. (1995) Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia. Nat. Genet., 10, 325-329.
36. Posey, K.L., Hayes, E., Haynes, R. and Hecht, J.T. (2004) Role of TSP-5/COMP in pseudoachondroplasia. Int. J. Biochem. Cell Biol., 36, 1005-1012.
37. Allen, J.R., Nguyen, L.X., Sargent, K.E., Lipson, K.L., Hackett, A. and Urano, F. (2004) High ER stress in beta-cells stimulates intracellular degradation of misfolded insulin. Biochem. Biophys. Res. Commun., 324, 166-170.
38. Katiyar, S.K. (2008) Grape seed proanthocyanidines and skin cancer prevention: inhibition of oxidative stress and protection of immune system. Mol. Nutr. Food Res., 52(Suppl 1), S71-S76.
39. Rao, C.V. (2007) Regulation of COX and LOX by curcumin. Adv. Exp. Med. Biol., 595, 213-226.
40. Welting, T.J., Caron, M.M., Emans, P.J., Janssen, M.P., Sanen, K., Coolsen, M.M., Voss, L., Surtel, D.A., Cremers, A., Voncken, J.W. et al. (2011) Inhibition of cyclooxygenase-2 impacts chondrocyte hypertrophic differentiation during endochondral ossification. Eur. Cell. Mater., 22, 420-436; discussion 436-427.
41. Hutchison, M.R. and White, P.C. (2015) Prostacyclin regulates bone growth via the Epac/Rap1 pathway. Endocrinology, 156, 499-510.
42. Kulkarni, S.S. and Canto, C. (2015) The molecular targets of resveratrol. Biochim. Biophys. Acta, 1852, 1114-1123.
43. Park, S.J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A.L. et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell, 148, 421-433.
44. Singh, N., Agrawal, M. and Dore, S. (2013) Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models. ACS Chem. Neurosci., 4, 1151-1162.
45. Funk, J.L., Frye, J.B., Oyarzo, J.N., Kuscuoglu, N., Wilson, J., McCaffrey, G., Stafford, G., Chen, G., Lantz, R.C., Jolad, S.D. et al. (2006) Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum., 54, 3452-3464.
46. Garcia Rodriguez, L.A., Hernandez-Diaz, S. and de Abajo, F.J. (2001) Association between aspirin and upper gastrointestinal complications: systematic reviewof epidemiologic studies. Br. J. Clin. Pharmacol., 52, 563-571.
47. Garcia Rodriguez, L.A. and Hernandez-Diaz, S. (2001) Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology, 12, 570-576.
48. Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., Fong, H.H., Farnsworth, N.R., Kinghorn, A.D., Mehta, R.G. et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-220.
49. Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K. et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444, 337-342.
50. Baur, J.A. and Sinclair, D.A. (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Dis., 5, 493-506.
51. Pearson, K.J., Baur, J.A., Lewis, K.N., Peshkin, L., Price, N.L., Labinskyy, N., Swindell, W.R., Kamara, D., Minor, R.K., Perez, E. et al. (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab., 8, 157-168.
52. Barger, J.L., Kayo, T., Pugh, T.D., Prolla, T.A. andWeindruch, R. (2008) Short-term consumption of a resveratrol-containing nutraceutical mixture mimics gene expression of long-term caloric restriction in mouse heart. Exp. Gerontol., 43, 859-866.
53. Barger, J.L., Kayo, T., Vann, J.M., Arias, E.B., Wang, J., Hacker, T.A., Wang, Y., Raederstorff, D., Morrow, J.D., Leeuwenburgh, C. et al. (2008) A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PloS One, 3, e2264.
54. Elmali, N., Esenkaya, I., Harma, A., Ertem, K., Turkoz, Y. and Mizrak, B. (2005) Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm. Res., 54, 158-162.
55. Wang, J., Gao, J.S., Chen, J.W., Li, F. and Tian, J. (2012) Effect of resveratrol on cartilage protection and apoptosis inhibition in experimental osteoarthritis of rabbit. Rheumatol. Int., 32, 1541-1548.
56. Smoliga, J.M., Baur, J.A. and Hausenblas, H.A. (2011) Resveratrol and health-a comprehensive review of human clinical trials. Mol. Nutr. Food Res., 55, 1129-1141.
57. Kidd, B.L. and Urban, L.A. (2001) Mechanisms of inflammatory pain. Br. J. Anaesth., 87, 3-11.
58. Mackey, S. (2004) Mechanisms of inflammatory pain: therapeutic implications. J. Clin. Rheumatol., 10, S5-S11.
59. Hui, W., Rowan, A.D., Richards, C.D. and Cawston, T.E. (2003) Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum., 48, 3404-3418.
60. Kobayashi, M., Squires, G.R., Mousa, A., Tanzer, M., Zukor, D.J., Antoniou, J., Feige, U. and Poole, A.R. (2005) Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum., 52, 128-135.
61. Westacott, C.I., Barakat, A.F., Wood, L., Perry, M.J., Neison, P., Bisbinas, I., Armstrong, L., Millar, A.B. and Elson, C.J. (2000) Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis. Osteo. Cart., 8, 213-221.
62. Reagan-Shaw, S., Nihal, M. and Ahmad, N. (2008) Dose translation from animal to human studies revisited. FASEB J., 22, 659-661.
63. Garcia, S., Dirat, B., Tognacci, T., Rochet, N., Mouska, X., Bonnafous, S., Patouraux, S., Tran, A., Gual, P., Le Marchand-Brustel, Y. et al. (2013) Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci. Transl. Med., 5, 203ra124.
64. Lichtenberger, L.M., Ulloa, C., Romero, J.J., Vanous, A.L., Illich, P.A. and Dial, E.J. (1996) Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats. Gastroenterology, 111, 990-995.
65. Obeid, G., Zhang, X. andWang, X. (1992) Effect of ibuprofen on the healing and remodeling of bone and articular cartilage in the rabbit temporomandibular joint. J. Oral Maxillofac. Surg., 50, 843-849; discussion 849-850.
66. Elmali, N., Baysal, O., Harma, A., Esenkaya, I. and Mizrak, B. (2007) Effects of resveratrol in inflammatory arthritis. Inflammation, 30, 1-6.
67. Mao, Q.Q., Bai, Y., Lin, Y.W., Zheng, X.Y., Qin, J., Yang, K. and Xie, L.P. (2010) Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Mol. Nutr. Food Res., 54, 1574-1584.
68. Csaki, C., Keshishzadeh, N., Fischer, K. and Shakibaei, M. (2008) Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem. Pharmacol., 75, 677-687.
69. Srinivasan, K. (2005) Plant foods in the management of diabetes mellitus: spices as beneficial antidiabetic food adjuncts. Int. J. Food Sci. Nutr., 56, 399-414.
70. Beal, M.F. and Shults, C.W. (2003) Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease. Biofactors, 18, 153-161.
71. Burdan, F., Staroslawska, E. and Szumilo, J. (2012) Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclooxygenase inhibitors. Pharmacol. Rep., 64, 521-527.
72. Posey, K.L., Hankenson, K., Veerisetty, A.C., Bornstein, P., Lawler, J. and Hecht, J.T. (2008) Skeletal abnormalities in mice lacking extracellular matrix proteins, thrombospondin-1, thrombospondin-3, thrombospondin-5, and type IX collagen. Am. J. Pathol., 172, 1664-1674.